|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 米罗加巴林>> 市场分析报告 |
米罗加巴林市场分析报告 |
|
Pain Management- New Discoveries and Treatment Options in Abuse Deterrent Era ... stage NCE pipeline drugs (Cebranopadol, Mirogabalin, NKT-181, AVP-923,…) and ... Fibromyalgia - Pipeline Review, H1 2018 Fibromyalgia - Pipeline Review, H1 2018 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H1 2018, provides an overview of the Fibromyalgia (Central Nervous System) pipeline ... Fibromyalgia Therapeutics: Market Research Report This report analyzes the Global market for Fibromyalgia Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for this market. Market data and analytics are ... India Pharmaceutical Manufacturing Market Size, Share & Trends Analysis Report By Dosage Form (Tablets, Injectables), By Manufacturing Type (In-house, Contract), By Therapeutic Category (Endrocrinology, Cardiovascular), And Segment Forecasts, 2024 - 2030 This report can be delivered to the clients within 2 Business Days India Pharmaceutical Manufacturing Market Growth & Trends The India pharmaceutical manufacturing market size is expected to reach USD 35.38 billion by 2030, growing at a CAGR of 10.5%, ... Therapeutic Class Overview: Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined. Current analgesics for persistent pain are relatively ineffective, are associated with significant adverse effects or abuse liability, and ... Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined. Current analgesics for persistent pain are relatively ineffective, are associated with significant adverse effects or abuse liability, and ... Japan Pharma Outlook 2016: JP Giants leaning in for becoming a Speciality Global Pharma ... late stage pipeline/new launch, Mirogabalin approval in Neuropathic Pain, Brintellix Cognition ... Global Diabetic Neuropathy Market - 2025 -2033 ... treatment uptake. Innovation in therapies like Mirogabalin in Japan demonstrates the region's focus ... |